Otsuka Pharmaceutical entered into a collaboration agreement to use SomaLogic’s proprietary aptamer technology to discover and develop novel diagnostic products and to design research tools that will enhance Otsuka’s discovery and development efforts. SomaLogic will receive research funding and will be entitled to receive a royalty on any marketed products developed as a result of [...]

• 412http://clsdf.com/2008/06/somalogic-otsuka-early-detection-diagnosis/SomaLogic+%2B+Otsuka+%3D+Early+Detection+%2B+Diagnosis2008-06-11+03%3A03%3A00admin

CLSDF has highlighted the history and relationship of Archemix to CO in previous posts; read about it (here). It has been a very busy 2008 thus far for the Cambridge-based aptamer therapeutics company who has now (I believe it is technically a – sub – based upon University Colorado orgins…?) licensed out the right to [...]

• 329http://clsdf.com/2008/02/archemix-%e2%80%93-milestone-pandemonium/Archemix+%E2%80%93+Milestone+Pandemonium2008-02-26+15%3A39%3A00admin

You may have seen the news yesterday on the Archemix and Merck KGaA deal for the use of the SELEX® technology in the oncology field. Well Cambridge and Germany are a long way from Colorado, or are they… The origins of the Archemix/Merck deal may be traced back to the first floor of Porter Bioscience, [...]

• 182http://clsdf.com/2007/06/selecting-a-selex%c2%ae-pathway/Selecting+a+SELEX%C2%AE+Pathway2007-06-12+15%3A41%3A00admin